ATEC Obtains Exclusive US Rights to OsteoAdapt® Platform in Major Strategic Alignment
Theradaptive Initiates Series B to Advance Proprietary Protein Engineering Technology
CARLSBAD, California and FREDERICK, Maryland, Jan. 12, 2026 /PRNewswire/ — Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing spine surgery, and Theradaptive, Inc., a clinical-stage regenerative medicine company pioneering engineered protein therapies, today announced a definitive strategic partnership agreement. At the same time, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein engineering platform into global therapeutic applications.
Under the terms of the agreement, ATEC obtains exclusive commercial rights in the US to market and distribute Theradaptive’s OsteoAdapt® osteoinductive bone graft for spinal fusion. This represents a landmark regenerative medicine partnership for the spine industry, structured to deliver significant long-term value through a combination of upfront and milestone payments and a perpetual royalty structure.
About the technology: Leveraging proprietary AMP2™ protein technology, OsteoAdapt is currently being evaluated in clinical trials in dental and spine applications and is subject to FDA PMA approval. The technology has received three breakthrough device designations from the FDA, underscoring its potential to address important unmet medical needs in bone regeneration.
“The partnership with Theradaptive represents an important milestone in the continued evolution of ATEC’s procedural ecosystem,” said Pat Miles, president and CEO of ATEC. “We have built a strong foundation of spinal procedural solutions across informatics, imaging, navigation and instrumentation, and the industry has long sought biological solutions that can further significantly improve fusion outcomes. OsteoAdapt is that solution. By integrating this innovative technology into our Organic Innovation Machine™, we are poised to set a new standard for clinical distinction in the spine.”
Theradaptive Series B Funding Initiation: To support the completion of clinical studies and rapid scaling of its technology platform alongside the ATEC partnership, Theradaptive has launched a Series B investment round. This capital will facilitate the advancement of the OASIS Pivotal trial in spinal fusion and the scale-up and development of manufacturing in support of future commercialization.
“In ATEC, we have found the ideal partner to bring this revolutionary technology to the patients who need it most,” said Luis Álvarez, Ph.D., founder and CEO of Theradaptive. “The synergy between our engineered protein platform and ATEC’s commercial reach, along with the initiation of our Series B round, ensures we are capitalized to deliver a new era of regenerative medicine.”
Market Opportunity: The US spine surgery market exceeds $10 billion annually, and the biologics segment represents a more than $2 billion opportunity. OsteoAdapt’s targeted approach represents a paradigm shift aimed at making traditional allografts and synthetic alternatives obsolete. Sustained sales growth from ATEC’s sales force provides confidence to maximize market penetration and return value to Theradaptive at current royalties.
About Alphatec Holdings, Inc.
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS Imaging SAS and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the company’s expanding InformatiX™ platform to better inform surgery and more safely and reproducibly achieve spine surgery goals. ATEC’s vision is to be the standard bearer in Spine. For more information, visit www.atecspine.com.
About Theradaptive, Inc.
Theradaptive is a privately held, clinical-stage biologics company developing protein therapies for spine, orthopedics, dental and soft tissue repair, and targeted therapies in various areas, including immuno-oncology. The company leverages its therapeutic delivery platform to deliver recombinant biologics to targeted areas of the body with high precision and persistence to address unmet medical needs. OsteoAdapt SP is an investigational device limited by US federal law to investigational use. For more information, visit www.theradaptive.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential commercial success and financial impact of the OsteoAdapt technology. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Neither company undertakes any obligation to update any forward-looking statements.
Contacts
Alphatec Holdings, Inc.
J. Todd Koning, Chief Financial Officer
investor relations@atecspine.com
Theradaptive, Inc.
Serena Santiago, Media and Investor Relations
Serena.santiago@theradaptive.com
Source: Alphatec Holdings, Inc. and Theradaptive, Inc.
SOURCE Theradaptive
